Fangxia Dihuang Decoction for psychosomatic symptoms in breast cancer chemotherapy

Phase 2, open-label, single-arm trial of fangxia dihuang decoction in breast cancer, anxiety disorder, major depressive disorder (MDD) and 3 more, sponsored by Xiamen Hospital of Traditional Chinese Medicine. Primary endpoints: Generalized Anxiety Disorder Scale (GAD) and Patient Health Questionnaire Depression Module (PHQ-9 or equivalent). Planned start Jun 2022; status: not yet recruiting.